Medical Therapies for Uterine Fibroids – A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Open Access
- 26 February 2016
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0149631
Abstract
Uterine fibroids are common, often symptomatic and a third of women need repeated time off work. Consequently 25% to 50% of women with fibroids receive surgical treatment, namely myomectomy or hysterectomy. Hysterectomy is the definitive treatment as fibroids are hormone dependent and frequently recurrent. Medical treatment aims to control symptoms in order to replace or delay surgery. This may improve the outcome of surgery and prevent recurrence. To determine whether any medical treatment can be recommended in the treatment of women with fibroids about to undergo surgery and in those for whom surgery is not planned based on currently available evidence. Two authors independently identified randomised controlled trials (RCT) of all pharmacological treatments aimed at the treatment of fibroids from a list of references obtained by formal search of MEDLINE, EMBASE, Cochrane library, Science Citation Index, and ClinicalTrials.gov until December 2013. Two authors independently extracted data from identified studies. A Bayesian network meta-analysis was performed following the National Institute for Health and Care Excellence—Decision Support Unit guidelines. Odds ratios, rate ratios, or mean differences with 95% credible intervals (CrI) were calculated. A total of 75 RCT met the inclusion criteria, 47 of which were included in the network meta-analysis. The overall quality of evidence was very low. The network meta-analysis showed differing results for different outcomes. There is currently insufficient evidence to recommend any medical treatment in the management of fibroids. Certain treatments have future promise however further, well designed RCTs are needed.Keywords
This publication has 112 references indexed in Scilit:
- Effect of low dose mifepristone on uterine leiomyoma in reproductive age groupFertility and Sterility, 2013
- Comparison of characteristics of fibroids in African American and white women undergoing premenopausal hysterectomyFertility and Sterility, 2013
- The estimated annual cost of uterine leiomyomata in the United StatesAmerican Journal of Obstetrics and Gynecology, 2012
- A randomized clinical trial of a levonorgestrel‐releasing intrauterine system and a low‐dose combined oral contraceptive for fibroid‐related menorrhagiaInternational Journal of Gynecology & Obstetrics, 2010
- Low‐dose mifepristone in treatment of uterine leiomyoma: A randomised double‐blind placebo‐controlled clinical trialAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2009
- CDB-2914 for Uterine Leiomyomata TreatmentObstetrics & Gynecology, 2008
- Effect of Mifepristone for Symptomatic Leiomyomata on Quality of Life and Uterine SizeObstetrics & Gynecology, 2006
- Leuprolide acetate treatment and myoma arterial sizeObstetrics & Gynecology, 1995
- GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: A randomized controlled trialObstetrics & Gynecology, 1995
- Treatment with GnRH agonists before myomectomy and the risk of short‐term myoma recurrenceBJOG: An International Journal of Obstetrics & Gynaecology, 1990